Proliferative vitreoretinopathy (PVR), the leading cause of rhegmatogenous retinal detachment (RRD) surgical failure, is a potentially blinding disease. The long-term project goal is to understand how cytokines trigger and perpetuate PVR. This information will lead to more effective treatment strategies designed to prevent or inhibit this condition, and will help to explain why some patients develop progressive disease while others do not. Based on data from the current funding period, the following hypotheses have been developed: The transcription factor NF-kappaB is a key regulator of cytokine expression in retinal pigment epithelial (RPE) cells, and inhibits RPE apoptosis. Cytokine-mediated, cell density-dependent activation of NF-kappaB in RPE cells promotes and perpetuates PVR. Contemporary cell and molecular biological techniques will be employed to address the following Specific Aims: I) To determine whether RPE cell density regulates interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFalpha)-mediated NF-kappaB activation. The effect of cell density on IL-1 and TNF receptor number and receptor-activated NF-kappaB activity will be quantified in cultured human RPE cells. II) To determine whether specific factors relevant to PVR or its treatment downregulate cytokine-activated NF-kappaB in RPE cells. The effect of transforming growth factor beta2 (TGF-beta2) and subretinal fluid from patients with RRD, on RPE cell NF-kappaB activation will be determined. III) To determine whether NF-kappaB regulates RPE cell apoptosis. Density-dependent effects of IL-1, TNFalpha, and specific NF-kappaB inhibitors on NF-kappaB-mediated RPE apoptosis will be quantified. IV) To determine whether specific in vivo NF-kappaB blockade inhibits PVR.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY009106-11
Application #
6615123
Study Section
Special Emphasis Panel (ZRG1-VISC (01))
Program Officer
Dudley, Peter A
Project Start
1992-01-01
Project End
2006-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
11
Fiscal Year
2003
Total Cost
$269,500
Indirect Cost
Name
Duke University
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Yang, Ping; Peairs, James J; Tano, Ryotaro et al. (2007) Caspase-8-mediated apoptosis in human RPE cells. Invest Ophthalmol Vis Sci 48:3341-9
Zhang, Nanfei; Peairs, James J; Yang, Ping et al. (2007) The importance of Bcl-xL in the survival of human RPE cells. Invest Ophthalmol Vis Sci 48:3846-53
Yang, Ping; Peairs, James J; Tano, Ryotaro et al. (2006) Oxidant-mediated Akt activation in human RPE cells. Invest Ophthalmol Vis Sci 47:4598-606
Yang, Ping; Wiser, Jessica L; Peairs, James J et al. (2005) Human RPE expression of cell survival factors. Invest Ophthalmol Vis Sci 46:1755-64
Tseng, Wendy; Cortez, Rafael T; Ramirez, Gema et al. (2004) Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 137:1105-15
Yang, Ping; McKay, Brian S; Allen, Janice B et al. (2004) Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci 45:2438-46
Yang, Ping; McKay, Brian S; Allen, Janice B et al. (2003) Effect of mutant IkappaB on cytokine-induced activation of NF-kappaB in cultured human RPE cells. Invest Ophthalmol Vis Sci 44:1339-47
Jaffe, Glenn J; Brownlow, Robert; Hines, John (2003) Modified external needle drainage procedure for rhegmatogenous retinal detachment. Retina 23:80-5
Park, Carl H; Jaffe, Glenn J; Fekrat, Sharon (2003) Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 136:419-25